In adult non-replicating tissues such as heart, demand for dNTPs (deoxynucleoside triphosphates) is low but essential for mitochondrial DNA replication and nuclear DNA repair. dNTPs may be synthesized from salvage of deoxyribonucleosides or by reduction of ribonucleotides. We have hypothesized that the cardiac mitochondrial toxicity of the nucleoside analogue AZT (3 -azido-3 -deoxythymidine; known as zidovudine) is caused by inhibition of thymidine kinase 2 of the salvage pathway and subsequent TTP pool depletion. The extent to which this hypothesis has merit depends on how much the heart relies on thymidine phosphorylation for maintenance of the TTP pool. In the present study, we used isotopic tracing to demonstrate that both TTP and dCTP are solely synthesized by phosphorylation of thymidine and deoxycytidine respectively, with no evidence for synthesis from other precursors. We have also shown that UTP and CTP are synthesized by phosphorylation of uridine and cytidine respectively, with no detectable role for the de novo pyrimidine synthesis pathway. Lastly, we have demonstrated that AZT decreased the TTP pool by 50 % in 30 min of perfusion, while having no effect on other dNTPs. In summary, the present study demonstrated that adult rat heart has a limited mechanism for dCTP and TTP synthesis and thus these pools may be more sensitive than replicating cells to drugs such as AZT that affect the salvage pathway.
INTRODUCTION
The generation of NTPs (ribonucleoside triphosphates) is required for RNA synthesis in all tissues. dNTPs (deoxynucleoside triphosphates) are necessary as a substrate for nuclear DNA replication, mtDNA (mitochondrial DNA) replication and nuclear DNA repair. In non-proliferating tissues, such as the isolated perfused rat heart, dNTPs are only used for mtDNA synthesis and nuclear DNA repair and thus the levels required are considerably reduced from that of a dividing cell. Cells have two potential pathways that can be used to make NTPs/dNTPs, the nucleoside or base salvage pathways or de novo synthesis. In the heart, the ribonucleotides have been shown to be largely derived from salvage of uridine and cytidine by the enzyme uridine-cytidine kinase (for a review, see [1] ). In mammals, the ability to salvage the bases uracil and cytosine has not been characterized. The role of the de novo pyrimidine pathway in adult heart is not clear, but if present is likely to be of low activity [1, 2] .
The origin of the deoxynucleotide pools in tissues such as the heart has never been specifically addressed. The salvage of deoxynucleosides from the blood represents the most efficient source. There are four deoxynucleoside kinases that have been well-characterized as rate-limiting in this pathway (for a review, see [3] ). Two are cytosolic: TK1 (thymidine kinase 1), which phosphorylates dT and dU, and dCK (dC kinase), which phosphorylates dC, dA and dG. The other two are localized in the mitochondrial matrix and include TK2 (thymidine kinase 2), which phosphorylates dT, dU and dC [4] , and deoxyguanosine kinase, which phosphorylates dA and dG [5] . Of these, expression of TK1 is regulated by the cell cycle and is present only in S-phase [6] , and is thus unlikely to be present in the adult rat heart. However, dNTPs can also be generated from ribonucleotides by the activity of ribonucleotide reductase. Ribonucleotide reductase is composed of homodimeric R1 subunits and two variants of a homodimeric subunit called R2 and p53-inducible R2. Although R1 is a relatively long-lived protein, the level of R2 is closely tied to S-phase of the cell cycle and quickly becomes limiting outside of S-phase. The level of the p53-inducible R2 rises in response to DNA damage and the need for nuclear DNA repair. However, it has previously been shown that there is low-level expression of an R1-p53R2 enzyme even in normal resting fibroblasts [7] , and that this pathway is an important source of dNTPs [8] . Treatment of such non-dividing cells with hydroxyurea, an inhibitor of ribonucleotide reductase, significantly lowered dNTP pools [7, 8] . There is also a report of a mitochondrial ribonucleotide reductase in HeLa cells [9] . The expression of ribonucleotide reductase activity in a non-replicating tissue, such as rat heart, has not been specifically addressed.
The importance of the origin of the deoxynucleotide pools can be illustrated by considering the synthesis of TTP. Previous work from our laboratory has shown that [ 3 H]dT is readily taken up by the perfused heart and converted into [ 3 H]TTP by the mitochondrial salvage pathway [10, 11] . The TTP produced in the mitochondrial matrix can be used for mitochondrial DNA replication or it can be exported to the cytoplasm, perhaps via the recently described pyrimidine nucleotide carrier PNC1 [12] , to be used by nuclear DNA. However, there are other potential sources of TTP which include: (i) salvage of dU by TK2 (mitochondrial) to dUMP, followed by conversion of dUMP into TMP by thymidylate synthase and dihydrofolate reductase; (ii) salvage of dC by dCK (cytoplasmic) or TK2 (mitochondrial) to dCMP, which would supply the cell with dCTP by further phosphorylation, or dCMP could be deaminated by dCMP deaminase to dUMP and converted into TMP as described above; and (iii) ribonucleosides could be used as a source of TTP, either via the salvage of uridine or cytidine to their monophosphates, or via the de novo synthesis of UMP. UMP could be phosphorylated to UDP and reduced to dUDP by ribonucleotide reductase. The dUDP is thought to follow a pathway that generates a transient dUTP that is quickly converted into dUMP by a highly active dUTP pyrophosphorylase that protects the cell from mutagenic levels of dUTP. Conversion of dUMP into TMP would continue as described above.
It is important to discern whether or not heart tissue has mechanisms other than the salvage of thymidine to yield TTP since many anti-cancer and anti-viral drugs that target cellular and viral DNA replication respectively are ribo/deoxyribonucleoside analogues that utilize the same metabolic pathways taken by the naturally occurring ribo/deoxyribo-nucleosides. This potentially leads to substrate competition for the phosphorylating enzymes between the naturally occurring deoxynucleosides and drugs. One such drug, AZT (3 -azido-3 -deoxythymidine; known as zidovudine), a member of the NRTI (nucleoside reverse transcriptase inhibitor) drug family, was commonly associated with cardiovascular mitochondrial toxicity in humans during the early days of high-dose monotherapy [13, 14] , as well as in experimental animal models [15, 16] . The general hypothesis that has been proposed to account for the mitochondrial toxicities of NRTIs is that the NRTI-triphosphates inhibit mtDNA polymerase γ activity resulting in reduced mtDNA replication and mtDNA depletion [17] [18] [19] . However, although this hypothesis has merit with regard to many NRTIs, it does not account for the toxicity of AZT in the perfused heart [10] . Rather, we have shown that AZT is a potent inhibitor of dT phosphorylation in the perfused heart and in isolated heart mitochondria [10, 20] , and we have suggested that this inhibition might deplete the TTP pool required for mitochondrial replication, leading to decreased mtDNA replication. The strength of this hypothesis is directly dependent on the degree to which the TTP pool of the heart is supplied primarily or solely by the phosphorylation and salvage of thymidine. Thus a main goal of the present experiments is to discern which precursors and pathways exist in the normal isolated perfused heart with the ability to make TTP. To accomplish this goal we perfused normal adult rat hearts with various 3 H-labelled precursors and followed the conversion of these precursors into ribo-and deoxyribo-nucleotides. As a part of the present study the primary origin of all of the ribo/deoxyribo-nucleotide pools in the adult perfused rat heart have been determined.
The results of the present study will demonstrate that no evidence for de novo synthesis of UMP was detected and both the ribo-and deoxyribo-nucleotides are generated by the salvage pathway. Uridine and cytidine are preferred substrates for the synthesis of UTP and CTP respectively, whereas uracil, but not cytosine, can be salvaged, but at low levels. The dCTP and TTP pools are obtained solely by the salvage of dC and dT respectively. Finally, we demonstrate in the perfused heart that inhibition of the dT salvage pathway by AZT for 30 min lowered TTP levels ∼ 50 %.
EXPERIMENTAL

Rat heart perfusion
Animal experimentation was carried out according to the appropriate institutional guidelines using a protocol approved by our Institutional Animal Care and Use Committee. Adult male outbred Sprague-Dawley rats (250-400 g) were obtained from Harlan Laboratories. The rats were injected with heparin [0.4 unit/g, i.p. (intraperitoneally)] in saline solution 10-45 min prior to perfusion and were subsequently anaesthetized with 1 ml of sodium pentobarbital (50 mg/ml, i.p.). Once anaesthetized, rats were incised below the diaphragm, the chest cavity was rapidly opened, and the heart was quickly removed by cutting the aorta. Hearts were immediately placed in 0.9 % ice-cold saline solution and placed via the aorta on a Langendorff retrograde perfusion apparatus and perfused at 37
• C using a modified Langendorff procedure as previously described [10] . Isolated hearts were perfused for 10 min to wash-out blood and exogenous components with non-recirculating Krebs-Henseleit perfusion buffer that was equilibrated with 95 % O 2 /5 % CO 2 and contained 15 mM glucose and plasma levels of amino acids. Following the wash-out period, hearts were perfused with recirculating Krebs-Henseleit perfusion buffer as described above supplemented with: 0. In order to have the best chance of observing conversion of orotate into other intermediates via the de novo pathway, orotate was not diluted with unlabelled compound and hearts were perfused at 0.15 μM labelled orotate at a specific radioactivity of 33 700 d.p.m./pmol. The isolated hearts were perfused at a constant pressure of 60 mmHg for a fixed time point of 1 or 2 h.
Perfused heart and perfusate preparation for HPLC analysis
Isolated hearts were removed from the Langendorff perfusion apparatus by freeze-clamping them in liquid nitrogen into thin heart wafers. From the heart wafers, ∼ 0.2 g pieces of heart were individually weighed and homogenized in 2 ml of 5 % trichloroacetic acid. The homogenate was precipitated on ice for 10 min, and then centrifuged for 3 min at 2000 g at 4
• C. The supernatant from each homogenized heart extract (1.5 ml) was neutralized by the addition of AG11A8 resin (0.5 g/ml of heart extract). Tubes with resin + heart extract sat on ice for 10 min, or were held overnight at −70
• C. The resin-treated extracts were vortexed until the sample pH was above 6.0, and then filtered into vials for analysis by HPLC. The unlabelled adenine nucleotide pool and the radiolabelled compounds were analysed by HPLC as described below.
A 0.5 ml sample was removed from the initial and final perfusates of each recirculating perfusion buffer for HPLC analysis. Each 0.5 ml perfusate sample was precipitated with 0.5 ml of 10 % trichloroacetic acid, chilled on ice for 10 min, and then microfuged at 4
• C, after which the same procedure used for the heart samples was followed.
HPLC analysis of perfused heart and perfusate samples
The labelled products of each labelled precursor were separated and quantified by reverse-phase HPLC over an Alltech nucleotide/nucleoside column connected to a UV detector (254 nm) and a Radiomatic flow-through scintillation counter as described previously [ . The ratio shifts to 90 % Buffer A and 10 % Buffer B over 12 min and then to 71 % Buffer A and 29 % Buffer B over the next 7 min using a concave gradient. The 71 % Buffer A/29 % Buffer B ratio is held for 6 min, changed to 69 % Buffer A and 31 % Buffer B for 2 min and then returns to 98 % Buffer A and 2 % Buffer B which is held for 8 min to re-equilibrate the column before the next run. A variety of pyrimidine nucleoside bases, deoxynucleosides, ribonucleosides and their phosphorylated forms were run as internal standards with each HPLC analysis as a reference for determining the potential radiolabelled peaks from each experiment. The adenine nucleotide peaks and the unlabelled internal standards were quantified by absorbance at 254 nm. The radioactive peaks were quantified by a scintillation counter flow cell positioned in the system 30 s after the UV monitor. The radioactive chromatograms were adjusted to match the UV chromatograms. The concentrations of the heart ribo-/deoxyribonucleoside and nucleotides were too low to be detected by the UV monitor, thus it was not possible to directly measure the specific radioactivity of the labels in the heart. As a result, the data for each chromatogram is expressed as d.p.m. per mg of heart wet weight.
Analysis of unlabelled dNTP pools in the perfused heart
The levels of dNTPs were determined in hearts perfused for 30 min as described above in the presence of 1 μM levels of all four deoxynucleosides and the presence or absence of 200 μM AZT. No radiolabelled nucleosides were used in the present experiment. The hearts were freeze-clamped in liquid nitrogen at the end of perfusion and were extracted as described above. The levels of dNTPs were determined using a template assay developed by Sherman and Fyfe [23] , and modified by Song et. al. [24] . In a separate control experiment, the recovery of [ 3 H]dNTPs added to the initial heart homogenates was >98 %.
RESULTS
Energy charge of the perfused heart
The goal of the present study was to determine the origin of NTPs and dNTPs, with an emphasis on potential alternative pathways of TTP synthesis. Work with nucleotide pools requires the maintenance of a good energy charge in each isolated perfused heart ([ATP] + 0.
To achieve this, hearts were freeze-clamped in liquid nitrogen while being perfused and the subsequent sample preparation (described above) was performed in a 4
• C cold room. The energy charge of each heart was determined as part of the HPLC analysis in which the peaks of adenosine, AMP, ADP and ATP were identified and quantified by a UV monitor at 254 nm. Energy charge ranged from 0.70-0.88 with a mean of 0.76 + − 0.01 (n = 35), in reasonable agreement with previously published values [25] . Results from hearts that had an energy charge of less than 0.70 were discarded.
The de novo pyrimidine pathway in the perfused heart
The product of the de novo pyrimidine pathway is UMP synthesized from aspartate, glutamine and ribose 5-phosphate. An essential enzyme of the pyrimidine de novo pathway is UMP synthase [26] . This enzyme has two catalytic domains; the first attaches phosphoribosyl pyrophosphate to orotate to yield OMP (orotidine monophosphate), which is then decarboxylated by a second domain of the same protein to UMP. Detection of this protein in the perfused heart can be determined by measuring the conversion of [ 3 H]orotate in the perfusion into UMP, UDP and UTP in the heart [1] . A representative HPLC chromatogram from a heart perfused with [ 3 H]orotate for 2 h is shown in Figure 1(B) . The orotate space [25] in the heart was 1.2 + − 0.1 ml/g (n = 3 hearts), indicating that orotate readily entered and equilibrated within the intracellular space of the heart. The labelled orotate remained largely as orotate (70.5 + − 3.0 %, n = 3 hearts; Figure 1B) , with a small amount reproducibly converted into peaks with retention times of 18 (4.2 + − 1.3 %, n = 3), 19 (11.3 + − 1.3 %, n = 3) and 24 (6.8 + − 1.4 %, n = 3) min. These peaks were not present in the initial or final perfusate and were only found in the heart, indicating conversion from orotate by activity of the heart. Although the retention times of these peaks suggested conversion into nucleotides, these peaks did not co-elute with any of the uridine nucleotides in the standard ( Figure 1A ). Heart samples with these labelled peaks were individually spiked with UMP, dUMP, UDP, UTP, dUTP, dCMP, dCDP, dCTP and TTP. None of these internal standards co-eluted with any of the orotate-labelled peaks. Thus orotate did not appear to give rise to any detectable uridine or cytidine ribonucleotides or deoxyribonucleotides, confirming that UMP synthase was poorly expressed, if at all, in adult hearts. Other investigators have shown that labelled orotate is very poorly incorporated into myocardial RNA [27] . The unidentified peaks may represent orotidine and phosphorylated forms of orotidine; however, standards to determine this point were prohibitively expensive. In the absence of UMP synthase, the enzyme(s) responsible for the conversion of orotate into orotidine have not been identified. This conversion could occur as a reaction of uridine or thymidine phosphorylase working in the anabolic direction, except that it has been reported that orotate is not a substrate of either of these phosphorylases [28] .
Metabolism of uridine and uracil to ribonucleotides
In the absence of a de novo pathway, UMP is typically thought to be synthesized from salvage of the nucleoside uridine by phosphorylation via one of two known uridine-cytidine kinases [29] . Salvage of the base uracil is less likely, since uracil phosphoribosyl transferase activity has not been characterized in mammalian tissues. To test for salvage of uridine and uracil in adult rat heart, hearts were perfused for 2 h with 1 μM Figure 2C ). The amounts of phosphorylated product generated by both labels was quantified using the initial perfusate specific radioactivities and yielded 992 + − 147 (n = 3) and 151 + − 83 (n = 4) pmol/g of heart wet weight for [ 3 H]uridine and [ 3 H]uracil respectively. These results suggest that uridine is much preferred to uracil as a substrate for UTP synthesis, at noted by others [1] . However, these results must be interpreted with caution as the specific radioactivities of the intracellular pools of uracil and uridine could not be measured. Since the hearts were perfused for 10 min with single pass buffer containing no substrates, the initial intracellular levels of uracil and uridine should be negligible and the perfusate specific radioactivity accurate, but the amount of unlabelled uracil and uridine produced during the recirculating perfusion is unknown. A large [ 3 H]uracil peak was identified in hearts perfused with [ 3 H]uridine, demonstrating that the heart expressed an active uridine phosphorylase (catabolic direction) converting uridine into uracil. Note that for either precursor, the UMP and UDP intermediates were not observed or were quite small, demonstrating that the initial synthesis of UMP via uridine-cytidine kinase is rate-limiting, and once formed is rapidly converted into UDP sugars and UTP. This was also observed for the phosphorylation pathway of dT [10] . Lastly, when hearts were perfused with labelled uridine, a small amount of CTP (∼ 2 % of UTP) was also detected. This indicated the presence of CTP synthase, which transfers an amido group from glutamine to UTP to make CTP. Finally, there was no evidence of dUTP, dUDP or any labelled dT compounds for either labelled uracil or uridine, suggesting that ribonucleotide reductase activity was not detectable in the adult rat heart.
Metabolism of cytidine and dC
Chromatograms from hearts perfused for 1 h with [ 3 H]cytidine or [ 3 H]dC are shown in Figure 3 . Labelled cytidine was readily taken up and converted by the heart into four major phosphorylated peaks that co-eluted with CMP, CDP, CTP and UTP ( Figure 3B ). The distribution of heart radioactivity in each peak equalled (n = 3 hearts): cytidine, 34. dC was also readily taken up by the heart and phosphorylated to three peaks that co-eluted with dCMP, dCDP and dCTP ( Figure 3C ). The distribution of radioactivity in each peak for dC equalled (n = 3): dC, 77.0 + − 1.6 %; dCMP, 12.3 + − 1.1 %; dCDP, 5.2 + − 0.7 %; and dCTP, 5.4 + − 1.2 %. There was little evidence of breakdown of either labelled cytidine or dC in the hearts or in the final perfusates. Whereas the concentration of dC in the perfusate remained constant over the 1 h of perfusion, the level of [ 3 H]cytidine declined to 30.7 + − 2.2 % (n = 3) of the original amount. This difference is accounted for in part by the larger pool of labelled ribonucleotides compared with deoxyribonucleotides in the heart, together with an expected higher rate of incorporation of CTP into heart RNA than would be predicted for incorporation of dCTP into mtDNA. Finally, there was no detectable evidence that any of the labelled cytidine was converted into peaks that could be identified as deoxynucleotides, suggesting that activity of ribonucleotide reductase could not be observed. To demonstrate this more clearly, an extract from a heart perfused with [ 3 H]cytidine (0.1 ml) was mixed with an extract from a heart perfused with [ 3 H]dC (0.2 ml) and the combined extract (0.10 ml) was analysed by HPLC in a similar manner as above ( Figure 3D ). All peaks from both extracts could be clearly identified. The separation of CMP and CDP from dCMP and dCDP was especially good and clearly indicated that dCMP and dCDP were below the limits of detection in the labelled cytidine extract (approx. 50 d.p.m.). Although a small amount of dCTP (<5 % of CTP) could be obscured by the much larger CTP peak, the complete lack of dCDP and dCMP argue strongly against this possibility. Several hearts were also perfused with [ 3 H]cytosine, which was taken up by the heart, but was largely unreactive, yielding only a tiny amount of uracil, perhaps by nonenzymatic deamination. No phosphorylated peaks were detected (results not shown). 
Metabolism of dU
There was no evidence for the synthesis of deoxynucleotides from the UTP or CTP pathways described above. Alternatively, deoxynucleotides can be synthesized by salvage of deoxynucleosides via kinases that are specific to this pathway. There is no mechanism to synthesize deoxynucleotides from the bases alone. We have already demonstrated that dT is readily converted into TTP via the heart mitochondrial TK2 pathway [10] . dU represents the precursor most closely related to dT for the potential synthesis of TTP. dU can be salvaged by TK1 or TK2 to dUMP and subsequently converted into TMP by thymidylate synthase and dihydrofolate reductase. To test for the expression of these activities in the isolated heart, hearts were perfused with [5,6- 3 H]dU for 2 h yielding the HPLC chromatogram shown in Figure 4(C) . The presence of a substantial uracil peak indicated the cleavage of dU to uracil and deoxyribose 1-phosphate by uridine phosphorylase. The levels of labelled dU and uracil in the final perfusates were 53 + − 7 and 46 + − 7 % (n = 8) respectively. Thus these hearts contained both labelled dU and labelled uracil, and the distinction between ribo-and deoxyribo-nucleotides must be carefully made. However, UTP and dUTP were separated by HPLC analysis and the labelled peak at ∼ 20 min clearly coeluted with UTP, but not dUTP, as illustrated with a spike of unlabelled dUTP standard ( Figure 4C ). To confirm this result, hearts were perfused with 1 μM [5, H]dU in the presence of 500 μM unlabelled uracil ( Figure 4D ). If the nucleotide peaks observed at 15 and 20 min retention time are derived from dU then they should be unaffected by the addition of uracil. On the other hand, if the peaks were derived from labelled uracil, then the large dilution in specific radioactivity should cause the peaks to disappear. As observed in Figure 4(D) , the peaks disappeared, indicating their synthesis from uracil. Since dU is reported to be a very good substrate for TK2, the failure to synthesize dUMP was somewhat unexpected. It is possible that dU is not transported into the mitochondrial matrix, and thus does not get phosphorylated.
Effect of AZT on dNTP levels in the perfused heart
AZT has previously been shown to inhibit dT phosphorylation in the perfused heart [10] . Since the results of the present study suggest that dT phosphorylation is the sole route of TTP synthesis, then the presence of AZT would be expected to decrease TTP synthesis and TTP levels. Hearts were perfused with 1 μM of all four unlabelled deoxynucleosides in the presence and absence of 200 μM AZT and the dNTP pool sizes measured as described in the Experimental section. The results shown in Figure 5 clearly demonstrate that while the addition of AZT had no effect on dATP, dGTP or dCTP pool levels, it reduced TTP levels ∼ 50 % (P < 0.01, n = 5).
DISCUSSION
The results from the present study confirmed previous work suggesting that cells of the adult rat heart did not synthesize pyrimidine nucleotides via the de novo pathway [1, 27] . Rather, these studies show that the primary source of UTP and CTP is uridine and cytidine respectively, although the base uracil, but not cytosine, was minimally salvaged. All four of these compounds have been measured in rat plasma at concentrations that range in different studies between 2 and 10 μM [30] . The salvage of uridine and cytidine by uridine-cytidine kinase has been well described [1] ; however, the mechanism of uracil salvage is unknown. Uracil has been reported to be a substrate for the orotate phosphoribosyl transferase domain of UMP synthase [31] , although evidence for this enzyme is weak since there was no conversion of orotate into UMP as shown in Figure 1 . Salvage of uracil has been shown to occur in extracts of PC12 cells [32] . The authors of this study [32] demonstrated that uracil salvage was dependent on the presence of ribose 1-phosphate and suggested that the activity was mediated by uridine phosphorylase functioning in an anabolic direction. The source of ribose 1-phosphate in the perfused heart is not clear, but could arise from the degradation of endogenous guanosine or adenosine by purine nucleotide phosphorylase. Finally, the low rate of conversion of uracil into UTP may also represent a weakly expressed bona fide uracil phosphoribosyl transferase [33, 34] . Two human genes have been identified with strong homology with lower eukaryotic uracil phosphoribosyl transferases [33, 34] . One has N-terminal homology with human uridine-cytidine kinase 1 and C-terminal homology with lower eukaryotic uracil phosphoribosyl transferases [33] . The other was identified as a human homologue of yeast uracil phosphoribosyl transferase [34] ; however, the purified recombinant protein of this human homologue could not be shown to have uracil phosphoribosyl transferase activity [34] , and may function in other ways.
While [35] who demonstrated that a significant amount of TTP was synthesized by an R1-p53R2 enzyme expressed in non-proliferating quiescent fibroblasts cells in culture. This may represent an important difference between the two systems. Although both fibroblasts and cells of the perfused heart were non-proliferating during these experiments, fibroblast cells can be converted back into mitotic cells with the right treatment, whereas cells of the heart cannot. As a result, there may be significant differences in the capability of gene expression.
Since there was no evidence of conversion of pyrimidine ribonucleotides into deoxyribonucleotides, dCTP and TTP must be synthesized from the three pyrimidine deoxynucleosides present in rat serum: dC (1.4-23 μM), dU (0.5 μM) and dT (1.0 μM) [30] . Results from the present study demonstrated that dCTP and TTP are synthesized solely by the salvage of dC and dT respectively. Furthermore support for the importance of the TK2 salvage pathway in non-replicating tissue can be found in humans that have an inherited deficiency of TK2 and suffer from severe mtDNA depletion and myopathy that is lethal in early childhood [36, 37] . Mitochondrial TTP levels were markedly decreased in mitochondria isolated from fibroblasts cultured from some of the affected patients [38] .
Although dU is a known substrate of TK2 [39] , there was no synthesis of dUMP, dUDP or dUTP, and no conversion into TTP in the isolated rat heart perfused with labelled dU. In recent work we have shown that [ 3 H]dU is readily phosphorylated in membrane-free extracts of isolated heart mitochondria, but only sparingly phosphorylated in intact isolated mitochondria (E. E. McKee and A.T. Bentley, unpublished work). These results suggest that dU is not transported into the matrix. In this regard there may be transport differences between mammalian species. It has been shown in human cells that the plasma membrane nucleoside transporter ENT1 (equilibrative nucleoside transporter 1) contains a mitochondrial localization signal and can be found in both the plasma membrane and the inner membrane of mitochondria [40] . This transporter is capable of transporting many different nucleosides, including dU; however, previous work has demonstrated that the ENT1 transporter in rodents does not have a mitochondrial localization signal and is not found on the inner membrane of mitochondria in rodents [40] . This finding led the authors of the rodent study [40] to suggest that the absence of this transporter in rodents may account for the difference in fialuridine toxicity between rodents, where it was non-toxic, and humans where it caused deaths associated with mitochondrial toxicity and liver failure in seven out of 15 humans in Phase I trials [40] . Thus the transport of dU, like fialuridine, might not be the same across species. Interestingly, if thymidylate synthase and dihydrofolate reductase are not expressed in heart tissue, then there would be nothing gained by salvaging dU to dUMP, since the product could not be converted into TMP, but could give rise to mutagenic levels of dUTP.
In adult non-replicating tissues such as the rat heart, the demand for dNTPs is considerably lower than in many growing tissues. Outside of what might be needed by nuclear DNA repair, the only necessity for dNTPs is mtDNA replication. Since mitochondria must turnover in all cells, mtDNA replication must continue throughout the lifetime of a cell to maintain an active population of mitochondria. The pathways of dNTP synthesis in the adult heart have never been addressed. In the present study it was shown that cells of the heart depend on transport of exogenous pyrimidine deoxynucleosides and the salvage pathway to generate dCTP and TTP pools. Earlier results from our laboratory demonstrated that the dT salvage pathway was competitively inhibited by AZT [10, 20] . Since the heart salvage pathway did not produce detectable amounts of AZT-TP, we proposed that the heart mitochondrial toxicity observed in association with AZT treatment may be caused by AZT interference with the ratelimiting step of dT phosphorylation, depleting the TTP pool. In the present study, we have demonstrated that dT salvage via TK2 is the only pathway in the normal heart that contributes to TTP synthesis and inhibiting this pathway decreased the TTP pool 50 % in 30 min.
The results of the present study represent acute results obtained from the normal adult rat heart. Additional studies are required to determine how the cells of the heart might respond to a potential depletion in the TTP pool. This response could include an up-regulation of the dT salvage enzymes, the induction of ribonucleotide reductase expression, and/or the induction of thymidylate synthase and dihydrofolate reductase.
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